Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.184 -0.056 (-4.48%)
Streaming Delayed Price Updated: 2:37 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Via ACCESSWIRE
News headline image
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Via ACCESSWIRE
News headline image
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024 ↗
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
News headline image
NanoViricides Has Filed its Quarterly Report
Via ACCESSWIRE
News headline image
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Via ACCESSWIRE
News headline image
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
Via ACCESSWIRE
News headline image
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
Via ACCESSWIRE
News headline image
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire ↗
Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns. 
Via InvestorPlace
News headline image
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
Via ACCESSWIRE
News headline image
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Via ACCESSWIRE
News headline image
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
Via ACCESSWIRE
News headline image
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment? ↗
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is. 
Via Benzinga
News headline image
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
Via ACCESSWIRE
News headline image
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024 ↗
NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco 
Via Benzinga
News headline image
NanoViricides to Present at the Biotech Showcase in San Fransisco
Via ACCESSWIRE
Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
--News Direct-- 
Via News Direct
Topics Death
News headline image
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
Via ACCESSWIRE
News headline image
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
Via ACCESSWIRE
News headline image
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
Via ACCESSWIRE
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
Via ACCESSWIRE
News headline image
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
Via ACCESSWIRE
News headline image
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗
Read the latest report on NanoViricides here 
Via Benzinga
News headline image
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗
Read the latest report on NanoViricides here 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
Via ACCESSWIRE
News headline image
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? ↗
Read the latest report on NanoViricides here. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.